Certolizumab in the long-term treatment of rheumatoid arthritis

References

• KveinTKEpidemiology and burden and illness of rheumatoid arthritisPharmacoeconomics2004222 Suppl 1112
   Web of Science ®Google Scholar
• ScottDLWolfeFHuizingaTWRheumatoid arthritisLancet20103761094110820870100
   PubMed Web of Science ®Google Scholar
• BathonJMMartinRWFleischmannRMA comparison of etanercept and methotrexatein patients with early rheumatoid arthritisN Engl J Med20003431586159311096165
   PubMed Web of Science ®Google Scholar
• St ClairEWvan der HeijdeDMSmolenJSCombination of infliximab and methotrexate therapy for early rheumatoid arthritisArthritis Rheum2004503432344315529377
   PubMed Web of Science ®Google Scholar
• BreedveldFCWeismanMHKavanaughAFA multicenter, randomised, double-blind clinical trial of combination therapy with adalimumabplus methotrexate versus methotrexate alone or adali-mumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis Rheum200654263716385520
   PubMed Web of Science ®Google Scholar
• SaagKGTengGGPatkarNMAmerican College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritisArthritis Rheum20085976278418512708
   PubMed Web of Science ®Google Scholar
• DeightonCO’MahonyRToshJTurnerCRudolfMGuideline Development GroupManagement of rheumatoid arthritis: summary of NICE guidanceBMJ2009338702
   PubMed Web of Science ®Google Scholar
• ToshJCWailooAJScottDLDeightonCMCost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritisJ Rheumatol2011381593160021572149
   PubMed Web of Science ®Google Scholar
• SfikakisPPThe first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directionsCurr Dir Autoimmun20101118021020173395
   PubMedGoogle Scholar
• ScallonBJMooreMATrinhHChimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functionsCytokine199572512597640345
   PubMed Web of Science ®Google Scholar
• MeasePAdalimumab in the treatment of arthritisTher Clin Risk Manag2007313314818360621
   PubMedGoogle Scholar
• DanilaMIHughesLBBridgesSLPharmacogenetics of etanercept in rheumatoid arthritisPharmacogenomics200891011101518681777
   PubMed Web of Science ®Google Scholar
• WongMZiringDKorinDTNFα blockade in human diseases: mechanisms and future directionsClin Immunol200812612113617916444
   PubMed Web of Science ®Google Scholar
• NesbittAFossatiGBerginMMechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agentsInflamm Bowel Dis2007131323133217636564
   PubMed Web of Science ®Google Scholar
• GramlickAFossatiGHenryAAssessment of the affinity for soluble TNF and the neutralising potency against soluble and membrane TNF of the anti-TNF agents certolizumab pegol, adalimumab, etanercept and infliximabAnn Rheum Dis200665456
   Web of Science ®Google Scholar
• FossatiGNesbittAIn vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents certolizumab pegol, adalimumab, etanercept and infliximabAnn Rheum Dis200665455
   Web of Science ®Google Scholar
• MpofuSFatimaFMootsRJAnti-TNF-alpha therapies: they are all the same (aren’t they?)Rheumatology20054427127315561736
   PubMed Web of Science ®Google Scholar
• FossatiGNesbittAEffect of the anti-TNF agents certolizumab pegol, adalimumab, etanercept and infliximab on levels of apoptosis in activated peripheral blood lymphocytes and monocytes and on necrosis and degranulation of peripheral blood granulocytesAnn Rheum Dis200665622
   Google Scholar
• ChoyEHHazlemanBSmithMEfficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trialRheumatology2002411133113712364632
   PubMed Web of Science ®Google Scholar
• KaushikVMootsRCDP-870 (certolizumab) in rheumatoid arthritisExpert Opin Biol Ther2005560160615934837
   PubMed Web of Science ®Google Scholar
• KeystoneEHeijdeDMasonDJrCertolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyArthritis Rheum2008583319332918975346
   PubMed Web of Science ®Google Scholar
• SmolenJLandeweRBMeasePEfficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trialAnn Rheum Dis20096879780419015207
   PubMed Web of Science ®Google Scholar
• FleischmannRVencovskyJvan VollenhovenREfficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD studyAnn Rheum Dis20096880581119015206
   PubMed Web of Science ®Google Scholar
• ArnettFEdworthySBlochDThe American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritisArthritis Rheum1988313153243358796
   PubMed Web of Science ®Google Scholar
• StrandVSmolenJVollenhovenRCertolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trialAnn Rheum Dis201170996100221415050
   PubMed Web of Science ®Google Scholar
• Ruiz GarciaVJobanputraPBurlsACertolizumab pegol (CDP870) for rheumatoid arthritis in adultsCochrane Database Syst Rev20112CD00764921328299
   PubMed Web of Science ®Google Scholar
• LaunoisRAvouacBBerenbaumFComparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysisJ Rheumatol20113883584521239748
   PubMed Web of Science ®Google Scholar
• FuchsHAKayeJJCallahanLFNanceEPPincusTEvidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of diseaseJ Rheumatol1989165855912754663
   PubMed Web of Science ®Google Scholar
• LindqvistEJonssonKSaxneTEberhardtKCourse of radiographic damage over 10 years in a cohort with early rheumatoid arthritisAnn Rheum Dis20036261161612810421
   PubMed Web of Science ®Google Scholar
• KavanaughAHanCBalaMFunctional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritisJ Rheumatol20043184985515124242
   PubMed Web of Science ®Google Scholar
• JansenLMvan der Horst-BruinsmaIEvan SchaardenburgDPredictors of radiographic joint damage in patients with early rheumatoid arthritisAnn Rheum Dis20016092492711557647
   PubMed Web of Science ®Google Scholar
• LandeweRvan der HeijdeDRadiographic progression in rheumatoid arthritisClin Exp Rheumatol200523S63S6816273787
   PubMed Web of Science ®Google Scholar
• Van der HeijdeDMvan RielPLNuver-ZwartIHEffects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritisLancet19891103610382565997
   PubMed Web of Science ®Google Scholar
• Van der HeijdeDHow to read radiographs according to the Sharp/van der Heijde methodJ Rheumatol19992674374510090194
   PubMed Web of Science ®Google Scholar
• LarsenADaleKEekMRadiographic evaluation of rheumatoid arthritis and related conditions by standard reference filmsActa Radiol Diagn (Stockh)197718481491920239
   PubMed Web of Science ®Google Scholar
• KavanaughASmolenJSEmeryPEffect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritisArthritis Rheum2009611592160019877104
   PubMed Web of Science ®Google Scholar
• ConnockMTubeufSMalottkiKCertolizumab pegol for the treatment of rheumatoid arthritisHealth Technol Assess201014Suppl 2110
   PubMed Web of Science ®Google Scholar
• SinghJAWellsGAChristensenRAdverse effects of biologics: a network meta-analysis and Cochrane overviewCochrane Database Syst Rev20112CD00879421328309
   PubMed Web of Science ®Google Scholar
• ScottDLCopeANew tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?Ann Rheum Dis20096876776919435722
   PubMed Web of Science ®Google Scholar
• HyrichKLLuntMWatsonKDOutcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort studyArthritis Rheum200756132017195186
   PubMed Web of Science ®Google Scholar
• HyrichKLLuntMDixonWGEffects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drugRheumatology2008471000100518420660
   PubMed Web of Science ®Google Scholar
• LloydSBujkiewiczSWailooAJSuttonAJScottDThe effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysisRheumatology2010492313232120566736
   PubMed Web of Science ®Google Scholar
• NesbittAFossatiGBrownDEffect of structure of conventional anti-TNFs and certolizumab pegol on mode of action in rheumatoid arthritisAnn Rheum Dis200766296
   Web of Science ®Google Scholar
• BarnesTMootsRTargeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegolInt J Nanomedicine200723717722505
   PubMed Web of Science ®Google Scholar
• Certolizumab pegol and rheumatoid arthritisJust another TNF alpha antagonist, no therapeutic advantagePrescrire Int201019279
   Google Scholar